Tamoxifen, contrary to erroneous information disseminated on the Internet, was established only in 1962. In 1971 the first clinical trials of the preparation were carried out. It was not until 1977 that the FDA approved a new drug for human use in the treatment of breast cancer. It is a popular means used during post-cycle therapy (PCT).
It has recently been shown that tamoxifen blocks dopamine. Ephedrine causes a low dopamine burst, phentermine slightly stronger, methamphetamine (very strong or medium depending on the type), amphetamine very strong. Amphetamine acts by norepinephrine (and inhibiting its reversible uptake), dopamine uptake (and inhibition of its reuptake) and weak (or medium) serotonin burst. It turned out that tamoxifen has a protective effect on the excessive release of dopamine. Tamoxifen blocked 54% uptake and 59% dopamine release from amphetamine.
Tamoxifen reduces hyperactivity caused by administration of amphetamine to rats but has no depressive or stimulatory effect.
The application of tamoxifen can also be used as a remedy for addicts such as amphetamines.
You can read also: Phenylalanine – support for dopamine production